Decreased Serum IL-22 Levels in Patients with Systemic Lupus Erythematosus

Hai-Feng Pan,Xue-Fei Zhao,Hui Yuan,Wen-Hui Zhang,Xiang-Pei Li,Gui-Hong Wang,Guo-Cui Wu,Xiao-Wu Tang,Wen-Xian Li,Lian-Hong Li,Jin-Bao Feng,Chun-Song Hu,Dong-Qing Ye
DOI: https://doi.org/10.1016/j.cca.2008.11.009
IF: 6.314
2009-01-01
Clinica Chimica Acta
Abstract:Multiple Sclerosis (MS) is an immune-mediated and neurodegenerative disease of central nervous system. Relapsing-remitting (RR)-MS occurring with acute attacks and remissions, is the most common clinical type of MS. There are different strategies applied in first-line treatment of RR-MS patients such as interferon-beta (IFN-β) and glatiramer acetate. In this study, activating and inhibitory receptor expressions and interleukin (IL)-22 levels of NK cells were investigated in RR-MS patients with or without IFN-β therapy. Activating receptor expression and IL-22 levels of NK cells were increased in RR-MS patients under IFN-β therapy. Elevated NK cells with activating profile and increased IL-22 under IFN-β therapy suggest that IFN-β treatment might direct NK cells toward a pro-inflammatory status.
What problem does this paper attempt to address?